Reply to thread

Thanks again DAN! Would this picture also include further divestitures (if the buy back doesn't work & the stock continues to tank?) i realize you don't have a crystal ball, but we seen a few suprises there (ANDA) and the company has other "unbranded" or branded assets such as biosimilars that don't fit "growth pharma" portfolio. Thanks!